RNACCartesian Therapeutics, Inc.

$218M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$34M+207.7% YoY

Gross Profit

$33M98.1% margin

Operating Income

$11M31.7% margin

Net Income

$29M84.6% margin

EPS (Diluted)

$6.77

QoQ Revenue Growth

+13.6%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$146M

Total Liabilities

$90M

Stockholders' Equity

$56M

Cash & Equivalents

$113M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$34M	$11M	+207.7%
Gross Profit	$33M	$11M	+201.9%
Operating Income	$11M	-$7M	+250.5%
Net Income	$29M	-$25M	+217.0%

RNAC Q1 2022 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena